BioElectron’s EPI-589 Shows Positive Results in ALS Patients in Phase 2a Trial

Investigational compound EPI-589 was found to be safe and well-tolerated, improved biomarkers of neuroinflammation, and showed signs of slowing disease progression in amyotrophic lateral sclerosis (ALS) patients, according to a completed Phase 2a clinical trial. BioElectron Technology Corporation’s EPI-589, or (R)-troloxamide quinone, is a 250 mg immediate-release, film-coated…